Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.88 |
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.64 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | PYGM | P11217 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165218 | 0.94 | PYGL (0.81) | PYGLCYP51A1CTNNB1EGFRPYGM | |
| SCHEMBL29362778 | 0.94 | PYGL (0.81) | PYGLCYP51A1CTNNB1EGFRPYGM | |
| SCHEMBL6165213 | 0.94 | PYGL (0.81) | PYGLCYP51A1CTNNB1EGFRPYGM | |
| SCHEMBL14587604 | 0.94 | PYGL (1.00) | PYGLCYP51A1CTNNB1EGFR | |
| SCHEMBL6161267 | 0.94 | PYGL (1.00) | PYGLCYP51A1CTNNB1EGFR | |
| SCHEMBL29357801 | 0.92 | PYGL (0.78) | PYGLCYP51A1CTNNB1EGFRPYGM | |
| SCHEMBL29359765 | 0.91 | PYGL (0.77) | PYGLCYP51A1CTNNB1EGFRPYGM | |
| SCHEMBL29359826 | 0.91 | PYGL (0.77) | PYGLCYP51A1CTNNB1EGFRPYGM | |
| SCHEMBL29358053 | 0.90 | PYGL (0.81) | PYGLCTNNB1 | |
| SCHEMBL6163437 | 0.87 | PYGL (0.74) | PYGLCYP51A1CTNNB1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289848-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12269899-B2 | Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289848-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | CTNNB1, CTNNBL1, CTNND1 | PYGL 184/4885CYP51A1 780/4885CTNNB1 1/4885 |
| US-12269899-B2 | Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction | CTNNB1, CTNNBL1, CTNND1 | PYGL 186/4885CYP51A1 695/4885CTNNB1 1/4885 |
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | CTNNB1, CTNNBL1, CTNND1 | PYGL 184/4885CYP51A1 780/4885CTNNB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.